(indan-2-yl)acetaldehyde | 146737-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (indan-2-yl)acetaldehyde
• 英文别名: 2-indanylacetaldehyde；2-(2,3-dihydro-1H-inden-2-yl)acetaldehyde；2-indanacetaldehyde
• CAS: 146737-67-9
• 化学式: C₁₁H₁₂O
• 分子量: 160.216
• InChiKey: XMQCVICRPBHGLO-UHFFFAOYSA-N

物化性质

• 沸点：
  273.0±9.0 °C(Predicted)
• 密度：
  1.044±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (indan-2-yl)acetaldehyde 在 sodium tetrahydroborate 、 sodium hydride 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 25.25h， 生成 3-Ethoxycarbonylmethyl-1-(2-indan-2-yl-ethyl)-4-oxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  A Rational Approach to the Design and Synthesis of a New Bradykinin B₁ Receptor Antagonist

  摘要：

  We have previously synthesized a potent and selective B-1 bradykinin receptor antagonist, JMV1645 (H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH), containing a dipeptide mimetic ((3S)-amino-5-carbonylmethyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (D-BT) moiety) at the C-terminal. Analogues of this potent B1 bradykinin receptor antagonist in which the central Pro(2)-Hyp(3)-Gly(4)-Igl(5) tetrapeptide has been replaced by constrained N-1-substituted-1,3,8-triazaspirol[4.5]decan-4-one ring system were synthesized. Among these analogues, compound JMV1640 (1) was found to have an affinity of 24.10 +/- 9.48 nM for the human cloned B-1 receptor. It antagonized the [des-Arg(10)]-kallidin-induced contraction of the human umbilical vein (pA(2) = 6.1 +/- 0.1). Compound 1 was devoid of agonist activity at the kinin B-1 receptor. Moreover, it did not bind to the human cloned B-2 receptor. Therefore, JMV1640 constitutes a lead compound for the rational search of nonpeptide B-1 receptor analogues based on the BK sequence.

  DOI：

  10.1021/jm990962k
• 作为产物：
  描述：

  2-茚满基乙酸 在 四丙基高钌酸铵 lithium aluminium tetrahydride 、 molecular sieve 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 CH₃CN 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 (indan-2-yl)acetaldehyde
  参考文献：
  名称：

  [EN] 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS
  [FR] IMIDAZOLE-2-ONES ET IMIDAZOLE-2-THIONES 4 SUBSTITUES COMME AGONISTES DES ADRENO-RECEPTEURS ALPHA-2B ET ALPHA-2C

  摘要：

  式(I)的化合物：其中X为S，变量的含义如规范中定义的那样，对alpha2B和/或alpha2C肾上腺素受体具有特异性或选择性，优先于alpha2A肾上腺素受体，并且因此具有无或仅有极小的心血管和/或镇静活性。这些式(I)的化合物在哺乳动物，包括人类中，作为药物用于治疗对alpha2B肾上腺素受体激动剂治疗有响应的疾病和/或缓解症状是有用的。式(I)的化合物，其中X为O，还具有有利的特性，即它们具有无或仅有极小的心血管和/或镇静活性，并且适用于治疗无或仅有极小的心血管和/或镇静活性的疼痛和其他症状。

  公开号：

  WO2003099795A1

文献信息

• Remedy for hyperlipidemia
  申请人：Zeria Pharmaceutical Co., Ltd.

  公开号：US05750524A1

  公开（公告）日：1998-05-12

  The invention relates to a remedy for hyperlipidemia, which comprises, as an active ingredient, an indane derivative represented by the general formula (1): ##STR1## wherein R.sup.1 means an alkyl group having 1-12 carbon atoms, a benzyl group, a styryl group, a naphthyl group, a phenyl group which may be substituted, or a thienyl group which may be substituted, R.sup.2 denotes a carboxyl group, an alkoxycarbonyl group having 1-4 carbon atoms, ##STR2## Y is a group represented by --(CH.sub.2).sub.p -- (p stands for an integer of 0-5), a group represented by --CO--(CH.sub.2).sub.q .about. or --CH(OH)--(CH.sub.2).sub.q .about. (q stands for an integer of 1-4, and .about. means bonding to R.sup.2), an oxymethylene group, or a vinylene group, and n stands for an integer of 1-4, or a pharmaceutically acceptable salt thereof, to use of this compound for the preparation of a remedy for hyperlipidemia, and to a method for treating hyperlipidemia by making good use of this compound.

  该发明涉及一种治疗高脂血症的药物，其活性成分为一种由通式（1）表示的茚衍生物：##STR1## 其中R.sup.1表示具有1-12个碳原子的烷基基团，苄基，苯乙烯基，萘基，可能被取代的苯基或可能被取代的噻吩基，R.sup.2表示羧基，具有1-4个碳原子的烷氧羰基，##STR2## Y表示--(CH.sub.2).sub.p --（p为0-5的整数），表示--CO--（CH.sub.2).sub.q .about.或--CH(OH)--（CH.sub.2).sub.q .about.（q为1-4的整数，.about.表示与R.sup.2结合），氧甲亚甲基基团或乙烯基团，n为1-4的整数，或其药学上可接受的盐，用于制备治疗高脂血症的药物的这种化合物的使用，以及通过充分利用这种化合物治疗高脂血症的方法。
• Direct Synthesis of Polysubstituted Aldehydes via Visible-Light Catalysis
  作者：Fengjin Wu、Leifeng Wang、Jiean Chen、David A. Nicewicz、Yong Huang

  DOI：10.1002/anie.201712384

  日期：2018.2.19

  competing reaction pathways, commercial styrenes react with vinyl ethers selectively in the presence of an acridinium salt photooxidant and a disulfide hydrogen‐atom‐transfer catalyst under blue LED irradiation. Alkyl aldehydes with different substitution patterns are prepared in good yields. This strategy can be applied to structurally sophisticated substrates.

  醛是合成化学中用途最广泛的官能团之一。但是，获得多取代烷基醛的途径非常有限，并且需要漫长的合成路线，其中涉及多步官能团转化。本文报道了使用可见光光氧化还原催化从易得的烯烃基质一步合成多取代醛的方法。尽管存在许多竞争性的反应途径，但在蓝色LED辐射下，在存在salt啶盐光氧化剂和二硫化氢氢原子转移催化剂的情况下，商品苯乙烯仍选择性地与乙烯基醚反应。制备具有不同取代方式的烷基醛的收率很高。该策略可以应用于结构复杂的基板。
• [EN] 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS<br/>[FR] IMIDAZOLE-2-ONES ET IMIDAZOLE-2-THIONES 4 SUBSTITUES COMME AGONISTES DES ADRENO-RECEPTEURS ALPHA-2B ET ALPHA-2C
  申请人：ALLERGAN INC

  公开号：WO2003099795A1

  公开（公告）日：2003-12-04

  Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

  式(I)的化合物：其中X为S，变量的含义如规范中定义的那样，对alpha2B和/或alpha2C肾上腺素受体具有特异性或选择性，优先于alpha2A肾上腺素受体，并且因此具有无或仅有极小的心血管和/或镇静活性。这些式(I)的化合物在哺乳动物，包括人类中，作为药物用于治疗对alpha2B肾上腺素受体激动剂治疗有响应的疾病和/或缓解症状是有用的。式(I)的化合物，其中X为O，还具有有利的特性，即它们具有无或仅有极小的心血管和/或镇静活性，并且适用于治疗无或仅有极小的心血管和/或镇静活性的疼痛和其他症状。
• 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same
  申请人：Heidelbaugh M. Todd

  公开号：US20050075366A1

  公开（公告）日：2005-04-07

  The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha 2B adrenergic receptors in preference over alpha 2A and alpha 2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2B adrenergic receptors.

  该化学式的化合物，其中*表示一个不对称碳原子，对α2B肾上腺素受体具有特异性，优先于α2A和α2C肾上腺素受体，因此几乎没有或仅有极小的心血管和/或镇静活性。该化合物可用作哺乳动物，包括人类，治疗对α2B肾上腺素受体激动剂治疗敏感的疾病和/或缓解症状的药物。
• Indane derivative and processes for preparing the same
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US05686452A1

  公开（公告）日：1997-11-11

  Disclosed are an indane compound represented by the formula: ##STR1## wherein R.sup.1 represents a lower alkyl group, a lower alkenyl group or a substituted or unsubstituted mono-cyclic aromatic heterocyclic group having nitrogen atom as a hetero atom; R.sup.2 represents hydrogen atom or a lower alkyl group; and A represents a lower alkylene group, or a pharmaceutically acceptable salt thereof and processes for preparing the same.

  公开了一种吲烷化合物，其由以下通式表示：##STR1##其中R1代表低级烷基、低级烯基或含有氮原子作为杂原子的取代或未取代的单环芳香杂环基团；R2代表氢原子或低级烷基；A代表低级亚烷基，或其药学上可接受的盐及其制备方法。